/PRNewswire/ NovelMed Therapeutics is a clinical-stage biotechnology company focused on developing anti-complement therapies for rare (orphan) diseases..
Alternative Pathway Blocker Anti-Bb Antibody (NM8074) Receives US FDA Clearance to Start Efficacy Trial in C3 Glomerulopathy (C3G) Patients streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ NovelMed Therapeutics, Inc. announced today interim positive results from a First-in-Human Phase I clinical trial of its complement blocker.
/PRNewswire/ NovelMed Therapeutics, Inc. announced today interim positive results from a First-in-Human Phase I clinical trial of its complement blocker.